Rhythm Biosciences (ASX:RHY)
ASX announcement history & article coverage
Transparent by design.
Announcments by Rhythm Biosciences (ASX:RHY) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Initial Director's Interest Notice - Carl Stubbings
Initial Director's Interest Notice - Maureen Baker
FY26 Appendix 4E & Audited Financial Report
Rhythm Biosciences reports $5.93m loss, achieves first commercial sales, and advances ColoSTAT® and geneType™ platforms
Appointment of Non-Executive Directors
Notification of cessation of securities - RHY
ColoSTAT Commercial Rollout Update
Bioshares 2026 Presentation
Quarterly Activities Report and Appendix 4C
Rhythm Biosciences strengthens balance sheet and expands ColoSTAT® commercial rollout in Q4 FY26
New Lung Cancer Genetype Risk Assessment Test
Accreditation Matters Conference Presentation
Rhythm launches tailored ColoSTAT marketing campaign